| |
Home »
News » 12/05 »
Sanofi-Aventis pre-pandemic flu vaccine safe
Sanofi-Aventis pre-pandemic flu vaccine safe
Date published:
15/12/2005
Sanofi-Aventis has released the preliminary trial results for
its influenza vaccine that show it is safe and well tolerated. The work carried
out by Sanofi Pasteur, the vaccine business of the Sanofi-Aventis group, was on
the drug H5N1 and demonstrated a good immune response in a significant number
of volunteers.
The trial also showed there were immune responses in
people who took lower doses, which future trials will explore and which could
be helpful when dealing with the widely discussed question of dose-sparing. The
data is now to be submitted the
European Agency for the
Evaluation of Medical Products (EMEA) and follow-up studies will focus on
using the vaccine on a large scale, mimicking a pandemic.
In the area of
preparing for a flu pandemic Sanofi Pasteur is expanding its production
capacity in the US and France and has agreed with the French government to
stockpile 1.4 million doses of H5N1.
The
World Health Organisation
has estimated the effect of a worldwide influenza pandemic on industrialised
nations would be as many as 650,000 deaths and 2.3 million hospitalisations.
© Adfero Ltd
Disclaimer
AllAboutMedicalSales excludes any warranty, express or implied, as to
the quality, accuracy, timeliness, completeness or fitness for a particular
purpose of this briefing. AllAboutMedicalSales will not be liable for any
claims, penalties, losses, damages, costs, or expenses arising from the use of
or inability to use this briefing or from any unauthorised access to or
alteration of the Briefing. AllAboutMedicalSales makes no warranty that the
contents of this briefing are compatible with all computer systems and
browsers.
|
